The metastatic spread of tumours is a complex phenomenon where a variety of factors are involved (Fidler & Hart, 1982; Nicolson, 1988) . Among the effects which occur is the invasion of tumour cells through surrounding tissues and then into adjacent blood and lymph vessels. This results in the dispersal of tumour cells which are subsequently able to colonise organs distant from the primary tumour. Metastatic clones often metastasise to favoured secondary sites including the lungs. Subsequent involvement of the pleura frequently results in the formation of a pleural effusion containing neoplastic cells (Cotran et al., 1989) . Sometimes extensive permeation of the sub-pleural lymphastics occurs and this is also a source of material forming the effusion.
Scatter factor is a -83,000 Mr protein which in vitro causes the dispersal of a wide variety of epithelial (Stoker & Perryman, 1985; Stoker et al., 1987) and also endothelial (Rosen et al., 1990a) cell colonies, and also significantly enhances the motility of the single cells. Addition of the factor causes a nearly complete loss of F-actin stress fibres identical to that which occurs when many cultured lines are transformed in culture (Dowrick & Warn, 1991) . Up to now it has been found to be largely paracrine in action, being secreted by fibroblasts (Stoker et al., 1987) and smooth muscle cells (Rosen et al., 1989) . It has also been found in significant quantities in human placenta and amniotic fluid (Rosen et al., 1990b) . Recently scatter factor has been identified as the same molecule as hepatocyte growth factor (Wiedner et al., 1991; Furlong et al., 1991) , which is a cytokine originally purified from the serum of patients with fulminant hepatic failure (Gohda et al., 1988) and rat platelets (Nakamura et al., 1987) and stimulates DNA synthesis in liver cells and a variety of other epithelial cell types (Kan et al., 1991) . It also corresponds to a molecule which has tumour cell toxicity effects (Shima et al., 1991 ). Weidner et al. (1990 found that the molecule stimulates the migration of responsive cells into collagen gels, mimicking the behaviour of tumour derived cells in vitro. Because of its properties HGF/SF is a candidate for having some role in metastatic spread. We have therefore screened the pleural effusion fluid of ten patients with metastatic spread to the pleura and one case of primary pleural malignancy, and identified its presence by several means in samples of several of these.
Materials and methods
Collection and processing of samples Pleural effusion samples were collected as the result of routine aspiration with 50-300 ml of aspirate usually being obtained at one time from a patient. The bulk was frozen after removing I ml for testing for scattering activity. This was spun in an Eppendorf microfuge for 1 min and assayed directly. If the sample was active the bulk was decanted and 200 ml spun in a Sorvall RC5B centrifuge for 30 min in a GSA rotor at 10,000 r.p.m. The clear supernatant was concentrated on Fast Flow S (Pharmacia, Milton Keynes) as described under Partial Purification below. HGF/SF was obtained from fresh human placenta essentially as described by Rosen et al. (1990b) . Fifty gm chopped term placenta was blended in an Atto-Mix (M.S.E., Loughborough) with phospate buffered saline (PBS) (2 ml gm placenta) containing 1 mm PMSF, 2 mM EDTA, and 25 sgm ml -' gentamicin for 4 min and centrifuged at 11,000 r.p.m. for 1 h in a Sorvall RC5B centrifuge using a GSA rotor. The supernatant was then taken for further purification. 10,000 units worth (cf. under Assay for scatter factor) of serum free medium containing secreted HGF/SF from MRC-5 cells (a human fibroblast lung line. ICN Flow, High Wycombe) and D4-3T3 cells (a murine fibroblast line, kind gift of Prof. M. Stoker) were directly concentrated on Fast Flow S (Pharmacia) as described below.
Partial purification All extracts were made up to 0.25 M NaCl and 25 mM MES and titrated to pH 6.0 prior to an initial purification step using Fast Flow S. For this 8 ml Fast Flow S preequilibrated with 0.25 M NaCl and 25 mM MES pH 6.0 was added to each sample and stirred gently for 30 min at room temperature. The gel was allowed to settle and the clear liquor decanted off. The resin was then poured into a HRIO/ 10 FPLC column (Pharmacia) and washed with buffer A (50 mM MES + 0.25 M NaCI) until the background adsorbance reached a base level. HGF/SF was then eluted with buffer B (50 mM MES + 1.0 M NaCI) collecting 2.5 ml fractions. After checking fractions for activity in dispersing MDCK colonies (cf. under Assay) the peaks of activity were further purified (after diluting with 3 vols of water to reduce the salt concentration) using a Mono S cation exchange column following the method of Gherardi et al. (1989) and eluting 0.5 ml fractions over the region where the peak of activity was likely to occur. For run where samples of different origins were mixed or runs sequentially on the same column, placenta and lung fractions which had been previously separated on a Mono S column were adjusted for similar activity and re-run. All lung samples were treated as category 2 material for safety reasons and because of this all operations involving the pleural effusion samples and placenta were carried out in a Howarth Class II safety hood. In these experiments effluent from the Fast Flow S column was directed into 96% ethanol. All column end fittings and valve parts of the FPLC were sprayed with 70% ethanol before and after connection.
Determination of the effects of heat and trypsin Nought point two ml samples of both pleural effusion fluid and HGF/SF from D4-3T3 cells were heated for 30 min at 60°C in a water bath. Nought point one ml was also added to 0.5 ml of 50 mM Tris buffer pH 8.4. Nought point two of this mixture was mixed with 50 ftl of immobilised trypsin (TPCK-trypsin, Pierce Chemical Co., Illinois, USA) previously washed with the Tris buffer. The mixture was incubated for 2 h at 37°C and the trypsin coated beads were spun down and decanted off. All samples were then tested for scattering activity in parallel with untreated controls.
Assay for scatter factor This was carried out as previously published by Stoker and Perryman (1985) . Briefly 5 x 103 MDCK cells were cultured overnight in the presence of serial 2-fold dilutions of test samples in Dulbecco's modification of Eagle's medium (DMEM) + 5% foetal calf serum in 96-well culture plates. The cells were then fixed in 4% formol-saline stained with Lofflers methylene blue and the lowest concentration determined at which scattering occurred. The highest sample dilution at which scattering was observed defined the titre of HGF/SF in the medium. Following Stoker and Perryman (1985) division of the titre by 0.3 gave the number of units of scatter factor per ml.
Immuno-assay The presence of HGF/SF was determined using a sensitive ELISA developed for its detection in the serum of patients with acute liver failure, as described in Tsubouchi et al. (1991) . This assay is specific for human HGF/SF and the antibody does not cross-react with mouse HGF/SF. The monoclonal antibody used in the ELISA does not cross-react with plasminogen, with which HGF/SF shows significant homology (Weidner et al., 1990) . This assay has recently been used to identify the presence of scatter factor in the medium of MRC 5 cells as part of the demonstration that scatter factor and hepatocyte growth factor are indeed the same molecule (Weidner et al., 1991) .
Results
An initial screen of pleural effusion fluids demonstrated a positive scattering effect in four out of 11 samples (Table I) (Stoker & Perryman, 1985) .
To determine whether this activity corresponded to that of HGF/SF, the elution profile of active factor on Mono-S cation-exchange columns was compared with that of spent tissue culture medium from MRC-5 and D4-3T3 cells, and also placenta extracts, Samples containing approximately equal amounts of activity were prepared from each of the four sources, as described. They were then added to and eluted sequentially from Mono-S columns. The resuls are shown in Figure 1 . As can be seen the peak activity for all the three samples of human origin eluted at 0.8 NaCl on the linear salt gradient. The slightly wider peaks for the lung and placenta samples were thought to be due to the greater protein concentrations being present. In contrast the peak fraction for the D4-3T3 sample consistently eluted at a slightly lower salt concentration of 0.7 NaCl. The same elution peak for all three human samples and the slightly earlier peak for the murine sample was also found when samples were run either alone or mixed together (not shown).
To directly demonstrate that the activity was indeed due to the presence of hepatocyte growth factor/scatter factor equivalent samples taken from the Mono S peaks were tested using the ELISA assay (Table II) . As can be seen semipurified pleural effusion fluid from the two patients was found to contain immunoreactive HGF/SF, as was placenta and the spent conditioned medium from MRC-5 cell cultures. In contrast murine D4-3T3 HGF/SF did not cross-react, as would be predicted. The levels of HGF/SF found using the ELISA assay were very variable. Pleural effusion fluid and placenta material gave fairly similar results when the ratio of scattering activity/immunoreactivity was determined. MRC-5 (Bradford 1976 ) while the MRC-5 eluant did not. Because equivalent samples gave similar levels of factor present using the MDCK colony scattering assay it may be that placenta contains a significant amount of inactive factor whilst that secreted by MRC-5 cells may be highly active but present in only small amounts. Alternatively the MRC-5 derived factor became degraded prior to immunoassay.
Discussion
Although the sample is not large, the finding of HGF/SF in the pleural effusion fluid of a proportion of samples of patients with metastatic spread to the pleura would seem to be significant. To date the only other case where hepatocyte growth factor/scatter factor has been identified as present in adult human tissues is in the serum of patients with fulminant liver failure (Gohda et al., 1988; Tsubouchi et al., 1991) . However, up to now little work has been done in determining its distribution in normal and diseased human tissues. A number of studies have identified that it is secreted by foetal lung fibroblasts of human origin in culture. These include the MRC 5 (Stoker & Perryman, 1985; Weidner et al., 1990) and M426 cell lines. In rats northern blot analysis has demonstrated that HGF/SF mRNA is synthesised within the normal lung . In situ hybridisation study revealed that the transcript was only weakly expressed in the normal rat lung but its presence could be enhanced by carbon tetrachloride (Noji et al., 1990) .
What then might be the source of the factor in the pleural effusion fluid? There are two possibilities. The first is that the factor is produced within the lung as part of an inflammatory response to the tumour. Sources of the factor could well be lung fibroblasts or possibly other cell types which the tumour comes into contact with as it infiltrates the lung tissue. The most likely alternative is that the tumour itself produces the factor. Up to now there have been two examples where epithelial cell lines in culture have been found to secrete the factor: the human keratinocyte line ndk (Adams et al., 1991) and the Chinese hamster (CHO) line (Verchueren et al., 1991 (Weidner et al., 1990) so it is quite possible that similar effects may occur in vivo leading to the spread of tumours through the tissues due to the loss or weakening of cell junctions between the epithelial cells. The receptor of HGF/SF has recently been identified as the product of the c-met proto-oncogene, Naldini et al., 1991) . c-met mRNA has ben identified in normal human lung tissue using Northern blots (Prat et al., 1991) . Furthermore a significant proportion of lung carcinomas (other than of the small cell type) were found to have significant levels of the receptor protein implying that they might respond to the presence of the factor, quite possibly by enhanced motility and/or by an increased cell division frequency.
It was somewhat surprising to find what may turn out to be rather high levels of HGF/SF in pleural effusion fluid. HGF/SF may well act only locally as other cytokines are thought to. Under normal cell growth conditions small amounts of factor would be expected to be present only briefly between secretion and binding to a receptor. The levels found may represent an acute situation, perhaps analogues to fulminant liver failure where HGF was originally identified (Gohda et al., 1988) . Such a situation may act to promote tumour growth and invasion.
